Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOI-A study of losartan-based matrix-directed therapy in older adolescents and adults with osteogenesis imperfecta
2024-515516-50-00Phase 2Authorised
- Sponsor
- Istituto Ortopedico Rizzoli
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, single-arm trial of losartan in osteogenesis imperfecta (OI), sponsored by Istituto Ortopedico Rizzoli. Primary endpoint: Percentage change in CTX from baseline to week 24. Planned start Sep 2025; status: authorised.
02
Drugs
losartan
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on 2024-515516-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515516-50-00.